Amedeo Smart

Free Medical Literature Service

 

Amedeo

Rheumatoid Arthritis
  Free Subscription

Articles published in
Clin Exp Rheumatol
    September 2025
  1. YANG W, Chen J, Wang X
    Rheumatoid arthritis: emerging insights into molecular mechanisms and targeted immunotherapy.
    Clin Exp Rheumatol. 2025 Sep 2. doi: 10.55563.
    >> Share

  2. ZHANG W, Zhuang D, Lu H, Lv Z, et al
    Predictions of rheumatoid arthritis burden in 204 countries and territories by 2044: based on the Global Burden of Disease Study 2021.
    Clin Exp Rheumatol. 2025 Sep 2. doi: 10.55563.
    >> Share

  3. NOTO G, Salvetti F, Demaj A, Altieri P, et al
    Pathogenesis of rheumatoid arthritis: one year in review 2025.
    Clin Exp Rheumatol. 2025;43:1533-1540.
    >> Share

  4. ISHII A, Nakayamada S, Ohkubo N, Miyazaki Y, et al
    Reduction of non-classical monocytes that suppress interferon-alpha in patients with systemic lupus erythematosus.
    Clin Exp Rheumatol. 2025;43:1568-1576.
    >> Share

    August 2025
  5. MOVAHEDI M, Li X, Cesta A, Bombardier C, et al
    COVID-19 in rheumatoid arthritis: prevalence, hospital admission, and risk of all-cause mortality before and after COVID-19 pandemic.
    Clin Exp Rheumatol. 2025 Aug 29. doi: 10.55563.
    >> Share

    July 2025
  6. MOLE EN, Tarassi AE, Tsirogianni AG, Athanasiades TE, et al
    Interaction of HLA-DRB1 shared epitope and smoking on the development of anti-citrullinated protein antibody positive rheumatoid arthritis in Greek patients.
    Clin Exp Rheumatol. 2025 Jul 25. doi: 10.55563.
    >> Share

  7. HU W, Xu Y
    Bibliometric insights into transforming the management of rheumatoid arthritis: three decades of progress against opportunistic infections.
    Clin Exp Rheumatol. 2025 Jul 22. doi: 10.55563.
    >> Share

  8. CHEN PK, Chen YM, Cho CF, Chen JJJW, et al
    A panel incorporating genetic variants of RIN3, NLRC3, and SLX4 shows promise in predicting remission after tofacitinib therapy in rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2025 Jul 21. doi: 10.55563.
    >> Share

    June 2025
  9. ZHENG Z, Liu X, Zhang Y, Zhang H, et al
    Research trends and hotspots on gut microbiota in rheumatoid arthritis: a bibliometric analysis from 2004 to 2024.
    Clin Exp Rheumatol. 2025 Jun 5. doi: 10.55563/clinexprheumatol/3899.
    >> Share

    May 2025
  10. OKANO T, Di Carlo M, Salaffi F, Filippucci E, et al
    Peritenon extensor tendon inflammation at metacarpophalangeal joints level: a valuable ultrasound finding in the differential diagnosis between psoriatic arthritis and rheumatoid arthritis?
    Clin Exp Rheumatol. 2025 May 31. doi: 10.55563.
    >> Share

  11. LI C, Zong S
    A comprehensive analysis of trends and inequalities in rheumatoid arthritis burden among women of childbearing age: insights from the Global Burden of Disease study 2021.
    Clin Exp Rheumatol. 2025 May 8. doi: 10.55563.
    >> Share

  12. KATSOULI O, Orfanos P, Lainis V, Katsouli P, et al
    Drug survival and predictor factors for discontinuation of first-line biologic therapy in rheumatoid arthritis: data from a real-world single-centre study.
    Clin Exp Rheumatol. 2025 May 8. doi: 10.55563.
    >> Share

  13. SONG Y, Ma J, Chu T, Wu M, et al
    Application of vascular index based on superb microvascular imaging technique for assessing disease activity in rheumatoid arthritis patients with signal-positive joints.
    Clin Exp Rheumatol. 2025 May 1. doi: 10.55563.
    >> Share

  14. ROSSI A, Ferrari G, Galli V, Bonacini M, et al
    Immunomodulatory effects of dental pulp stem cells on lymphocytes and monocytes from patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2025;43:809-814.
    >> Share

    April 2025
  15. OUDART F, Thomas M, Combier A, Molto A, et al
    Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice.
    Clin Exp Rheumatol. 2025 Apr 29. doi: 10.55563.
    >> Share

  16. KIM JW, Lee SK, Shin K, Jung JY, et al
    Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents.
    Clin Exp Rheumatol. 2025 Apr 18. doi: 10.55563/clinexprheumatol/z9894.
    >> Share

  17. DE MALEPRADE B, Gerard B, Brevet P, Riou G, et al
    Macrophage requirements for abatacept response in rheumatoid arthritis.
    Clin Exp Rheumatol. 2025 Apr 9. doi: 10.55563.
    >> Share

    March 2025
  18. WANG X, He J, Zhong J, He J, et al
    Hydroxychloroquine inhibits the PI3K/AKT pathway in synovial fibroblasts of rheumatoid arthritis and alleviates collagen-induced arthritis in mice.
    Clin Exp Rheumatol. 2025 Mar 28. doi: 10.55563.
    >> Share

  19. PENDOLINO M, Serban T, Ferrari G, Diana P, et al
    STEp-down approach in MEthotrexate use for the Treatment of Rheumatoid Arthritis (STEMETRA): a pilot study demonstrating efficacy and safety of short-term, high dose methotrexate.
    Clin Exp Rheumatol. 2025 Mar 20. doi: 10.55563.
    >> Share

  20. WU YK, Zhou L, Chang G, Wang RQ, et al
    Identification and validation of fibroblast-related biomarkers in rheumatoid arthritis by bulk RNA-seq and single-cell RNA-seq analysis.
    Clin Exp Rheumatol. 2025 Mar 20. doi: 10.55563.
    >> Share

  21. CHO MR, Kim YE, Lee YJ, Ahn SM, et al
    Risk of cervical intraepithelial neoplasia during Janus kinase inhibitor treatment in patients with rheumatoid arthritis: a retrospective cohort study.
    Clin Exp Rheumatol. 2025 Mar 13. doi: 10.55563.
    >> Share

  22. CHEN LF, Lin TM, Chang YS, Hsu HC, et al
    Effect of TNF-alpha blockers on reducing the risk of dementia in rheumatoid arthritis: a nationwide cohort study.
    Clin Exp Rheumatol. 2025 Mar 13. doi: 10.55563.
    >> Share

  23. YU M, Wu J, Zhang S, Yan W, et al
    RBM15, an m6A enzyme, suppresses NLRP3 inflammasome activation in rheumatoid arthritis through macrophage metabolism.
    Clin Exp Rheumatol. 2025 Mar 5. doi: 10.55563.
    >> Share

  24. CHENG S, Xu K, Hou W, Qin X, et al
    Integrated analysis of genome-wide copy number variation and exome-wide rare variation identified novel loci for rheumatoid arthritis.
    Clin Exp Rheumatol. 2025;43:459-466.
    >> Share

    February 2025
  25. ZHOU Q, Zhu S, Dai S, Wu Q, et al
    Comparison of the efficacy of Janus kinase inhibitors and adalimumab in rheumatoid arthritis: a meta-analysis.
    Clin Exp Rheumatol. 2025 Feb 13. doi: 10.55563.
    >> Share

  26. TIAN Y, Jin M, Li H, Li D, et al
    Advancements in rheumatoid arthritis immunotherapy: a comprehensive bibliometric analysis of research trends and hotspots (2003-2023).
    Clin Exp Rheumatol. 2025 Feb 11. doi: 10.55563.
    >> Share

  27. NAMAS RA, El-Kaissi M, Memisoglu E, Khan S, et al
    Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and mortality in a large single-centre cohort.
    Clin Exp Rheumatol. 2025 Feb 11. doi: 10.55563.
    >> Share

    January 2025
  28. AKASAKI Y, Yamada H, Kondo M, Fukushi JI, et al
    Cluster analysis identifies the differential impact of disease activity and severity on functional status and patient satisfaction in rheumatoid arthritis: the FRANK registry.
    Clin Exp Rheumatol. 2025 Jan 14. doi: 10.55563.
    >> Share

  29. HAGEGE O, Brevet P, Gerard B, Duhamel E, et al
    Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism.
    Clin Exp Rheumatol. 2025;43:87-95.
    >> Share

    December 2024
  30. ZHANG G, Yao L, Zhu Q, Herrmann M, et al
    Cross-reactivity of anti-modified protein antibodies in rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Dec 20. doi: 10.55563.
    >> Share

  31. SUZUKI K, Akiyama M, Kaneko Y
    Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review.
    Clin Exp Rheumatol. 2024 Dec 20. doi: 10.55563.
    >> Share

  32. WU J, Li D
    Pilocarpine treatment of Sjogren's syndrome curative effect of meta-analysis of randomised controlled trials.
    Clin Exp Rheumatol. 2024;42:2490-2498.
    >> Share

  33. LIU S, Chen C, Zheng Q, Sun H, et al
    Non-negligible prevalence of focal lymphocytic sialadenitis in minor salivary glands of non-Sjogren's disease individuals.
    Clin Exp Rheumatol. 2024;42:2499-2506.
    >> Share

  34. SLUIJPERS NRF, Fadhil M, Stel AJ, Dijkstra PU, et al
    Reliability of colour Doppler ultrasonography of the major salivary glands in Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2476-2482.
    >> Share

  35. BANDEIRA M, Fisher BA
    The effect of smoking on Sjogren's disease development and severity: a comprehensive literature review.
    Clin Exp Rheumatol. 2024;42:2346-2356.
    >> Share

  36. STANO S, Cacciapaglia F, Rinaldi A, Giannotta M, et al
    Anti-aquaporin-5 and anti-poly-U-binding-factor-60kDa protein antibodies in primary Sjogren's disease patients: preliminary data and correlation with disease activity indices.
    Clin Exp Rheumatol. 2024;42:2420-2426.
    >> Share

  37. NAKSHBANDI U, Liefers SC, Arends S, Spijkervet FKL, et al
    Abatacept use for 24 weeks has a limited effect on salivary gland inflammation in Sjogren's disease patients.
    Clin Exp Rheumatol. 2024;42:2362-2368.
    >> Share

  38. TROMBY F, Manfre V, Chatzis LG, Arends S, et al
    Clinical manifestations, imaging and treatment of Sjogren's disease: one year in review 2024.
    Clin Exp Rheumatol. 2024;42:2322-2335.
    >> Share

  39. GIOVANNINI I, De Martino M, Manfre V, Lorenzon M, et al
    Ultrasonographic scores and parotid histopathology in Sjogren's disease: challenges in lymphoma identification.
    Clin Exp Rheumatol. 2024;42:2483-2489.
    >> Share

  40. AUSMA NS, van der Kraan YM, de Wolff L, Kokol H, et al
    Field testing and clinical validation of the mSQUASH to measure physical activity in patients with Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2468-2475.
    >> Share

  41. BALDINI C, Chatzis LG, Fulvio G, La Rocca G, et al
    Pathogenesis of Sjogren's disease: one year in review 2024.
    Clin Exp Rheumatol. 2024;42:2336-2343.
    >> Share

  42. DE MARCHI G, Nano A, Fulvio G, Manfre V, et al
    Sjogren's disease and systemic lupus erythematosus overlap syndrome as distinct entity at crossroads of two autoimmune disorders: clinical characterisation from two Italian reference centres for both the diseases.
    Clin Exp Rheumatol. 2024;42:2453-2458.
    >> Share

  43. CHATZIS LG, Goules AV, Baldini C, Pezoulas VC, et al
    The clinical phenotype of isolated ocular or oral dryness in Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2507-2512.
    >> Share

  44. TSAI HC, Liao HT, Chen WS, Lai CC, et al
    Reduced Deltex1 expression in T cells indicates increased disease activity in Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2459-2467.
    >> Share

  45. PALLA P, Chatzis LG, Sipsas NV, Goules AV, et al
    Infections in Sjogren's disease: a clinical concern or not?
    Clin Exp Rheumatol. 2024;42:2531-2541.
    >> Share

  46. MEINECKE A, Kreis K, Olson P, Hoeper JR, et al
    Impact of time to diagnosis in patients with primary Sjogren's syndrome: a cross-sectional study.
    Clin Exp Rheumatol. 2024;42:2444-2452.
    >> Share

  47. HA YJ, Lee JI, Choi SR, Kang EH, et al
    Implications of thyroid-related autoantibodies in patients with Sjogren's syndrome without overt thyroid diseases.
    Clin Exp Rheumatol. 2024;42:2404-2411.
    >> Share

  48. LIU Q, Xing X, He J
    Tofacitinib alleviated salivary gland inflammation and reduced the percentages of effector T cells in murine Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2437-2443.
    >> Share

  49. LI X, Zhang S, Cheng T, Wang J, et al
    The abnormal expression of peripheral blood CD4+ T lymphocyte subsets are correlated with primary Sjogren's syndrome complicated with haematological involvement.
    Clin Exp Rheumatol. 2024;42:2412-2419.
    >> Share

  50. D'AGOSTINO GENNARI J, Deveza GBH, Ribeiro CT, Seguro AC, et al
    Efficacy of N-acetylcysteine for treating dryness symptoms of Sjogren's disease: randomised placebo-controlled double-blind clinical study.
    Clin Exp Rheumatol. 2024;42:2427-2436.
    >> Share

  51. KIM SH, Min HK
    Clinical utility of salivary and lacrimal gland ultrasonography in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2520-2530.
    >> Share

  52. LONGHINO S, Treppo E, Manfre V, De Martino M, et al
    The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjogren's disease: a monocentric cohort study.
    Clin Exp Rheumatol. 2024;42:2387-2392.
    >> Share

  53. DENG C, Wang A, Li W, Chen Y, et al
    The role of imbalanced CD226/TIGIT on activated peripheral double-negative T cells in the pathogenesis of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2369-2377.
    >> Share

  54. CHEN W, Chen W, Xia N, Yan R, et al
    Investigation of pyroptosis-related hub genes and the immune microenvironment in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2393-2403.
    >> Share

  55. KOMORI K, Komori M, Horino T, Nishiyama S, et al
    Influence of doctor-patient relationships and health-related factors on the medical satisfaction of patients with Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2378-2386.
    >> Share

  56. SONG Y, Zhou W
    Role of TLR7 in the pathogenesis of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2513-2519.
    >> Share

    November 2024
  57. VAN GEEL EH, Boers M, Hartman L, Smulders YM, et al
    Does high hepatic bioavailability enhance the effect of oral compared to subcutaneous glucocorticoids?
    Clin Exp Rheumatol. 2024;42:2265-2267.
    >> Share

  58. WANG K, Jiang Y, Zhai J, Zhang P, et al
    WNT16 as a promising biomarker for systemic lupus erythematosus and its role in regulating cell proliferation and apoptosis.
    Clin Exp Rheumatol. 2024;42:2206-2214.
    >> Share

  59. SON Y, Korenfeld D, Suarez-Fueyo A, Ruzek M, et al
    Understanding mechanisms of JAK1 inhibition on synovial fibroblasts using combinatorial approaches of bulk and single cell RNAseq analyses.
    Clin Exp Rheumatol. 2024;42:2194-2205.
    >> Share

    October 2024
  60. RUYSSEN-WITRAND A, Dimeglio C, Nogue E, Molinary N, et al
    Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts.
    Clin Exp Rheumatol. 2024 Oct 17. doi: 10.55563/clinexprheumatol/48440.
    >> Share

  61. VAN COMPERNOLLE K, Selleslag D, Hazlewood GS, Storek J, et al
    Allogeneic stem cell transplantation in difficult-to-treat rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Oct 17. doi: 10.55563.
    >> Share

  62. LA FERRARA R, Lazzaro FG, Alonzi G, Fiore S, et al
    Ultrasound versus clinical remission in patients with early rheumatoid arthritis: concordance and relationship with therapy discontinuation.
    Clin Exp Rheumatol. 2024 Oct 15. doi: 10.55563.
    >> Share

  63. FOURNIER J, Boussat B, Dervaux B, Gaudin P, et al
    Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis.
    Clin Exp Rheumatol. 2024 Oct 3. doi: 10.55563.
    >> Share

  64. OKA H, Sumitomo S, Shimizu H, Ohmura K, et al
    Markedly elevated serum IL-6 levels predict relapse within six months of treatment initiation in Still's disease.
    Clin Exp Rheumatol. 2024;42:2100-2101.
    >> Share

    September 2024
  65. D'ORAZIO A, Cirillo AL, Greco G, Di Ruscio E, et al
    Pathogenesis of rheumatoid arthritis: one year in review 2024.
    Clin Exp Rheumatol. 2024;42:1707-1713.
    >> Share

  66. HAN M, Ha JW, Jung I, Kim CY, et al
    Association between Mycobacterium tuberculosis infection and the risk of inflammatory arthritides.
    Clin Exp Rheumatol. 2024;42:1812-1819.
    >> Share

    August 2024
  67. QIAN Y, Zhang B, Nian F
    The association between rheumatoid arthritis and left ventricular diastolic dysfunction: pathogenesis, predictors and managements.
    Clin Exp Rheumatol. 2024 Aug 20. doi: 10.55563.
    >> Share

  68. MIN HK, Lee JY, Lee SH, Ju JH, et al
    Suppressing anti-citrullinated protein antibody-induced osteoclastogenesis in rheumatoid arthritis using anti-CD64 and PAD-2 inhibitors.
    Clin Exp Rheumatol. 2024 Aug 8. doi: 10.55563.
    >> Share

    July 2024
  69. MIN HK, Lee JY, Lee SH, Kim HR, et al
    Interleukin-18 binding protein regulates mast cell activation and mast cell induced osteoclastogenesis of rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Jul 25. doi: 10.55563.
    >> Share

  70. WIENTJES MHM, van Huissteden J, van Herwaarden N, Verhoef LM, et al
    Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab.
    Clin Exp Rheumatol. 2024 Jul 24. doi: 10.55563.
    >> Share

  71. ZHANG Y, Shi J, Xie Y, Shao H, et al
    Exploring the supplementary potential of all-trans retinoic acid with methotrexate in rheumatoid arthritis: modulation of synovial cell apoptosis and autophagy.
    Clin Exp Rheumatol. 2024 Jul 8. doi: 10.55563.
    >> Share

  72. OTA T, Ota SI
    Impact of anti-human IgG hinge peptide antibodies on identification of patients with early seronegative rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Jul 5. doi: 10.55563.
    >> Share

  73. RUZZON F, Adami G
    Environment and arthritis.
    Clin Exp Rheumatol. 2024;42:1343-1349.
    >> Share

  74. MONTAGNON PY, Beauger M, Couderc M, Tournadre A, et al
    Haptoglobin blood assay to assess treatment compliance in rheumatoid arthitis patients treated with tocilizumab.
    Clin Exp Rheumatol. 2024;42:1516.
    >> Share

  75. VIVEIROS L, Neves A, Gouveia T, Isenberg DA, et al
    A large cohort comparison of very late-onset systemic lupus erythematosus with younger-onset patients.
    Clin Exp Rheumatol. 2024;42:1480-1486.
    >> Share

    June 2024
  76. MOVAHEDI M, Choquette D, Coupal L, Keystone E, et al
    Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world data.
    Clin Exp Rheumatol. 2024 Jun 6. doi: 10.55563.
    >> Share

  77. LIU X, Wu L, Chen S, Liang X, et al
    Group 3 innate lymphoid cells promotes Th17 cells differentiation in rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Jun 6. doi: 10.55563.
    >> Share

  78. MAIOLI G, Cincinelli G, Biggioggero M, Caporali R, et al
    The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience.
    Clin Exp Rheumatol. 2024 Jun 4. doi: 10.55563.
    >> Share

    May 2024
  79. KANG T, Xi Y, Qian T, Lu S, et al
    Exploring the link between dietary omega-3 and omega-6 fatty acid intake and rheumatoid arthritis risk: NHANES 1999-2020 study.
    Clin Exp Rheumatol. 2024 May 6. doi: 10.55563.
    >> Share

  80. CICIRIELLO S, Littlejohn GO, Treuer T, Gibson KA, et al
    Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.
    Clin Exp Rheumatol. 2024 May 1. doi: 10.55563.
    >> Share

  81. MOLTENI E, Adinolfi A, Bondi V, Delvino P, et al
    Novel insights into the management of rheumatoid arthritis: one year in review 2024.
    Clin Exp Rheumatol. 2024;42:947-960.
    >> Share

  82. SHU CC, Chen PS, Lin ZH, Hsiao CT, et al
    Prevalence and risk factors of non-tuberculous mycobacterial pulmonary isolates and infection in interstitial lung disease associated with systemic autoimmune disease.
    Clin Exp Rheumatol. 2024;42:1006-1014.
    >> Share

  83. CHEN HW, Huang CH, Huang CF, Chang CH, et al
    Distinct subsets of synovial fibroblasts control cartilage destruction in joint diseases.
    Clin Exp Rheumatol. 2024;42:1118-1126.
    >> Share

    April 2024
  84. FORNARO M, Caporali R, Biggioggero M, Bugatti S, et al
    Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry.
    Clin Exp Rheumatol. 2024 Apr 17. doi: 10.55563.
    >> Share

  85. KIM JW, Shin K, Jung J, Suh CH, et al
    Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO Registry.
    Clin Exp Rheumatol. 2024 Apr 16. doi: 10.55563.
    >> Share

  86. KONG X, Wang W
    Association between Life's Essential 8 and all-cause or cardiovascular-specific mortality in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Apr 5. doi: 10.55563.
    >> Share

    March 2024
  87. GILDEMEISTER N, Redeker I, Buehring B, Andreica I, et al
    Prevalence of remission in patients with rheumatoid arthritis in daily clinical practice: long-term data from a tertiary care centre.
    Clin Exp Rheumatol. 2024 Mar 26. doi: 10.55563.
    >> Share

  88. SEBASTIANI M, Zabotti A, Biasi B, Cacioppo S, et al
    Factors associated of long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population.
    Clin Exp Rheumatol. 2024 Mar 26. doi: 10.55563.
    >> Share

  89. KANNAYIRAM S, Schmukler J, Li T, Goodson N, et al
    Elevated DAS28-ESR in patients with rheumatoid arthritis who have comorbid fibromyalgia is associated more with tender joint counts than with patient global assessment or swollen joint counts: implications for assessment of inflammatory activity.
    Clin Exp Rheumatol. 2024 Mar 22. doi: 10.55563.
    >> Share

  90. LEBEL N, Marie I, Grosjean J, Brevet P, et al
    Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases.
    Clin Exp Rheumatol. 2024.
    >> Share

  91. FLIPO RM, Constantin A, Goupille P, Chartier M, et al
    Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study.
    Clin Exp Rheumatol. 2024 Mar 3. doi: 10.55563.
    >> Share

  92. WU Y, Li X, Ke J, Zhang B, et al
    Increased expression of omentin-1 is associated with synovitis and bone destruction in rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Mar 3. doi: 10.55563.
    >> Share

  93. KUMARADEV S, Roux C, Sellam J, Perrot S, et al
    Do subjective components of disease activity contribute to heterogeneity in opioid prescriptions in inflammatory rheumatic diseases? Results from ESPOIR and DESIR cohorts.
    Clin Exp Rheumatol. 2024;42:671-681.
    >> Share

    February 2024
  94. KHULLAR A, Dhir V, Saikia B, Yadav AK, et al
    Rheumatoid arthritis synovial fluid shows enrichment of T-cells producing GMCSF which are polyfunctional for TNFalpha and IFNgamma.
    Clin Exp Rheumatol. 2024 Feb 12. doi: 10.55563.
    >> Share

  95. CEN X, Chen Y, Liu H, Luo Y, et al
    Methotrexate inhibits LPS-induced glycolysis in fibroblast-like synoviocytes isolated from patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Feb 6. doi: 10.55563.
    >> Share

  96. FEDERICO JA, Syvaranta SA, Tuohinen SS, Holmstrom MM, et al
    Myocardial T1 mapping by cardiac magnetic resonance imaging shows early myocardial changes in treatment-naive patients with active rheumatoid arthritis and positive autoantibodies.
    Clin Exp Rheumatol. 2024 Feb 6. doi: 10.55563.
    >> Share

    January 2024
  97. ALP G, Cinakli H, Kurut Aysin I, Solmaz D, et al
    Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives.
    Clin Exp Rheumatol. 2024 Jan 31. doi: 10.55563.
    >> Share

  98. GUO N, Li X, Movahedi M, Cesta A, et al
    Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry.
    Clin Exp Rheumatol. 2024 Jan 31. doi: 10.55563.
    >> Share

  99. LA BARBERA L, Rizzo C, Camarda F, Atzeni F, et al
    Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience.
    Clin Exp Rheumatol. 2024 Jan 8. doi: 10.55563.
    >> Share

  100. MARTINEZ-FEITO A, Plasencia-Rodriguez C, Novella-Navarro M, Gehin JE, et al
    Influence of rheumatoid factor on serum drug levels of tumour necrosis factor inhibitors with different structures in rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Jan 8. doi: 10.55563.
    >> Share

  101. CHEN CH, Liao HT, Chen HA, Yen YN, et al
    Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis.
    Clin Exp Rheumatol. 2024 Jan 5. doi: 10.55563.
    >> Share

  102. SHI L, Yang J, Xu J, Dai J, et al
    Elevated serum soluble CD27 levels are associated with both disease activity and humoral immune activity in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Jan 2. doi: 10.55563.
    >> Share

  103. DOBIES B, White AJ, Isberg A, Gudmundsson SF, et al
    Digital health program improves quality of life in rheumatoid arthritis: a retrospective analysis of real-world data.
    Clin Exp Rheumatol. 2024;42:10-14.
    >> Share

    December 2023
  104. TAN YK, Lim GH
    Assessment of joint inflammation at the wrist of patients with rheumatoid arthritis: thermography findings closely mirror those from ultrasonography.
    Clin Exp Rheumatol. 2023 Dec 7. doi: 10.55563.
    >> Share

  105. HOFSTEDT O, Wahlin B, Sodergren A
    Associations between serological biomarkers and subclinical atherosclerosis in patients with rheumatoid arthritis after 11 years of follow-up.
    Clin Exp Rheumatol. 2023 Dec 4. doi: 10.55563.
    >> Share

  106. FULVIO G, La Rocca G, Chatzis LG, Ferro F, et al
    Impact of gender and age at onset on Sjogren's syndrome presentation and outcome: state of the art.
    Clin Exp Rheumatol. 2023;41:2547-2554.
    >> Share

  107. TOMIZAWA T, Cox T, Kollert F, Bowman SJ, et al
    The impact of concomitant Sjogren's disease on rheumatoid arthritis disease activity: a systematic review and meta-analysis.
    Clin Exp Rheumatol. 2023;41:2484-2492.
    >> Share

  108. LONGHINO S, Chatzis LG, Dal Pozzolo R, Peretti S, et al
    Sjogren's syndrome: one year in review 2023.
    Clin Exp Rheumatol. 2023;41:2343-2356.
    >> Share

  109. COLAFRANCESCO S, Simoncelli E, Priori R, Bombardieri M, et al
    The pathogenic role of metabolism in Sjogren's syndrome.
    Clin Exp Rheumatol. 2023;41:2538-2546.
    >> Share

  110. MANFRE V, Parisi S, Caligiuri I, Repetto O, et al
    Secretagogue effect of PDE4 inhibitor apremilast on human salivary gland organoids obtained from primary Sjogren's syndrome patients.
    Clin Exp Rheumatol. 2023;41:2493-2501.
    >> Share

  111. JIANG T, Guo J, Wang Y, Wu H, et al
    Total glucosides of paeony alleviates experimental Sjogren's syndrome through inhibiting NLRP3 inflammasome activation of submandibular gland cells.
    Clin Exp Rheumatol. 2023;41:2502-2510.
    >> Share

  112. BALDINI C, La Rocca G, Fulvio G, Grossi E, et al
    Artificial neural network and deep learning in Sjogren's disease: where we are and where we are going.
    Clin Exp Rheumatol. 2023;41:2360-2362.
    >> Share

  113. COLAFRANCESCO S, Celia AI, Baldini C, Quartuccio L, et al
    Clinical and histological features of patients with primary Sjogren's syndrome and autoimmune thyroiditis: a national multicentre cross-sectional study.
    Clin Exp Rheumatol. 2023;41:2389-2396.
    >> Share

  114. SLUIJPERS NRF, Delli K, De Wolff L, Stel AJ, et al
    Longitudinal evaluation of major salivary gland functioning in Sjogren's disease patients in a prospective standard-of-care cohort.
    Clin Exp Rheumatol. 2023;41:2474-2483.
    >> Share

  115. DELLI K, Van Nimwegen JF, Arends S, Stel AJ, et al
    Can ultrasound of the major salivary glands differentiate Sjogren's disease from its major mimics?
    Clin Exp Rheumatol. 2023;41:2467-2473.
    >> Share

  116. VAN SANTEN JS, Assy Z, Bikker FJ, Laine ML, et al
    The diagnostic power of salivary electrolytes for Sjogren's disease: a systematic literature review and meta-analysis.
    Clin Exp Rheumatol. 2023;41:2511-2524.
    >> Share

  117. ZABOTTI A, Giovannini I, Longhino S, Manfre V, et al
    Nuts and bolts of salivary gland pathology in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2023;41:2525-2537.
    >> Share

  118. MARTINEZ-NAVA GA, Lopez-Reyes A, Hernandez-Hernandez C, Ruiz-Gonzalez V, et al
    Characterisation of crevicular fluid microbiota in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2023;41:2458-2466.
    >> Share

  119. GROOTELAAR RGJ, van Ginkel MS, Nienhuis PH, Arends S, et al
    Salivary gland 18F-FDG-PET/CT uptake patterns in Sjogren's syndrome and giant cell arteritis patients.
    Clin Exp Rheumatol. 2023;41:2428-2436.
    >> Share

  120. BARTOLONI E, Perricone C, Cafaro G, Gerli R, et al
    Cardiovascular risk in patients with Sjogren's syndrome: is it time for a new approach?
    Clin Exp Rheumatol. 2023;41:2357-2359.
    >> Share

  121. FLORES-CHAVEZ A, Brito-Zeron P, Ng WF, Szanto A, et al
    Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2023;41:2437-2447.
    >> Share

  122. BRITO-ZERON P, Flores-Chavez A, Ng WF, Fanny Horvath I, et al
    Exposure to air pollution as an environmental determinant of how Sjogren's disease is expressed at diagnosis.
    Clin Exp Rheumatol. 2023;41:2448-2457.
    >> Share

  123. YANG J, Xu J
    Autologous haematopoietic stem cell transplantation for primary Sjogren's syndrome with severe refractory thrombocytopenia: a case report.
    Clin Exp Rheumatol. 2023;41:2557-2558.
    >> Share

  124. AKIYAMA M, Yoshimoto K, Kaneko Y
    Significant association of CX3CR1+CD8 T cells with aging and distinct clinical features in Sjogren's syndrome and IgG4-related disease.
    Clin Exp Rheumatol. 2023;41:2409-2417.
    >> Share

  125. BARRIO-CORTES J, Gomez-Gascon T, Benito-Sanchez B, Dominguez-Berjon MF, et al
    Utilisation of primary healthcare services by Sjogren's syndrome patients in the Community of Madrid and associated factors: a population-based cross-sectional study.
    Clin Exp Rheumatol. 2023;41:2397-2408.
    >> Share

  126. ANTOINE P, Morell-Dubois S, Maillard H, Wojtasik G, et al
    Six medico-psycho-social dimensions of a pedagogical model used to define clusters of patients with Sjogren's syndrome and intentionality to participate in a patient education programme.
    Clin Exp Rheumatol. 2023;41:2379-2388.
    >> Share

  127. LIU Y, Guo L, Lin W, Ning X, et al
    Anticentromere antibody positive patients with primary Sjogren's syndrome have distinctive clinical and immunological characteristics.
    Clin Exp Rheumatol. 2023;41:2371-2378.
    >> Share

  128. CRUZ-BAUTISTA I, Almeda-Valdes P, Lopez-Carrasco G, Antonio-Villa N, et al
    High levels of rheumatoid factor: association with thyroid antibodies and other analytical thyroid interferences in Sjogren's syndrome.
    Clin Exp Rheumatol. 2023;41:2555-2556.
    >> Share

  129. PARK Y, Lee JJ, Koh JH, Kim MJ, et al
    Kynurenine pathway can be a potential biomarker of fatigue in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2023;41:2363-2370.
    >> Share

    November 2023
  130. QI W, Li F, Wang G, Yan Y, et al
    The effects of mesenchymal stem cells-derived exosomes in rheumatoid arthritis: a review.
    Clin Exp Rheumatol. 2023 Nov 23. doi: 10.55563.
    >> Share

  131. GOVONI M, Batalov A, Boumpas DT, D'Angelo S, et al
    Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-alpha inhibitor therapy: a pooled analysis of European prospective observationa
    Clin Exp Rheumatol. 2023 Nov 15. doi: 10.55563.
    >> Share

  132. WITTE T, Kiltz U, Haas F, Riechers E, et al
    The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study.
    Clin Exp Rheumatol. 2023 Nov 15. doi: 10.55563/clinexprheumatol/11255.
    >> Share

    October 2023
  133. FORSS A, Sotoodeh A, van Vollenhoven RF, Ludvigsson JF, et al
    Prevalence of coeliac disease in patients with rheumatoid arthritis and juvenile idiopathic arthritis: a systematic review and meta-analysis.
    Clin Exp Rheumatol. 2023 Oct 25. doi: 10.55563.
    >> Share

  134. LI S, Shi Y, Fang W, Feng Y, et al
    A bidirectional Mendelian randomisation study of the association between rheumatoid arthritis and frailty.
    Clin Exp Rheumatol. 2023 Oct 25. doi: 10.55563.
    >> Share

  135. AMMITZBOLL C, Thomsen MK, Andersen JB, Jensen JMB, et al
    Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
    Clin Exp Rheumatol. 2023 Oct 23. doi: 10.55563.
    >> Share

  136. CORDEIRO RA, Antonelli IPB, Giardini HAM
    Adult-onset Still's disease with ankylosis of the distal interphalangeal joints: beyond psoriatic arthritis.
    Clin Exp Rheumatol. 2023;41:2126-2127.
    >> Share

  137. LIN YH, Chang SH, Hsu TC, Chen PK, et al
    Elevated monocyte distribution width in patients with active adult-onset Still's disease: a novel activity indicator.
    Clin Exp Rheumatol. 2023;41:2062-2070.
    >> Share

    September 2023
  138. CAO S, Liu X, Li Y, Yang Y, et al
    Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease.
    Clin Exp Rheumatol. 2023 Sep 22. doi: 10.55563.
    >> Share

  139. LO PIZZO M, La Barbera L, Rizzo C, Mohammadnezhad L, et al
    JAK/STAT inhibition modifies the ILC1 immune response in patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2023 Sep 21. doi: 10.55563.
    >> Share

  140. GOU Y, Zhang J, Li C, Liu Y, et al
    Causal relationship between gut microbiota and rheumatoid arthritis: a two-sample Mendelian randomisation study.
    Clin Exp Rheumatol. 2023 Sep 15. doi: 10.55563.
    >> Share

  141. PISANI F, Croia C, Petrelli F, Chericoni E, et al
    The multifaceted role of mast cells in the pathogenesis of rheumatoid arthritis.
    Clin Exp Rheumatol. 2023 Sep 7. doi: 10.55563.
    >> Share

  142. MANZO C, Nune A, Castagna A
    Why would immuno- and endocrino-senescence, age-related changes in the gut microbiota, and susceptibility to infection favour polymyalgia rheumatica over seronegative elderly-onset rheumatoid arthritis?
    Clin Exp Rheumatol. 2023;41 Suppl 135:25-26.
    >> Share

  143. ABACAR KY, Aydin-Tatli I, Colakoglu S, Inanc N, et al
    Paraffin stimulation might not be necessary for the collection of saliva: effect on the rate and cellular distribution in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2023;41 Suppl 135:18-19.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016